BP003074: Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and ALLAVGATK peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003892: Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003894: Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP005768: Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and RMFPNAPYL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer protein with the C-His-Avi tag at 1 ug/ml (100 ul/Well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Antibody protein with the C-hFc tag with the EC50 of 14.2 ng/ml determined by ELISA (QC Test). The affinity constant of 0.18 nM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP005373: Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and RMFPNAPYL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer protein with the C-His-Avi tag at 2 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Antibody protein with the C-hFc tag with the EC50 of 19.0 ng/ml determined by ELISA (QC Test). The affinity constant of 0.33 nM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004268: Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and LMLGEFLKL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004269: Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and LMLGEFLKL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003508: Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer protein with the C-His-Avi tag at 1 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant HLA-A*02:01&B2M&PRAME TCR with the EC50 of 9.5 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003509: Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003075: Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and ALYVDSLFFL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer protein with the C-His-Avi tag at 1 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Antibody protein with the C-hFc tag with the EC50 of 6.7 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.